Braveheart Bio (BRVE) CFO Rickey James Paul Buys $500K of Stock

What Happened
Rickey James Paul, Chief Financial Officer of Braveheart Bio, reported two transactions: an open-market purchase of 27,777 shares at $18.00 each on 2026-08-07 for a total of $499,986, and a 300,000-share derivative award reported on 2026-08-05 (reported as $0.00). The purchase is an outright buy (often viewed as a bullish signal by investors); the 300,000-share item is a grant/award (derivative), not a cash sale.

Key Details

• Transaction dates and amounts:
  • 2026-08-07: Open-market purchase (Code P) — 27,777 shares @ $18.00 = $499,986.
  • 2026-08-05: Grant/award (Code A, derivative) — 300,000 shares @ $0.00.
• Vesting: Footnote states the derivative award vests 1/48th monthly beginning July 23, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• Beneficial ownership disclaimer: Reporting person disclaims beneficial ownership except to extent of pecuniary interest (footnote).
• Timeliness: Form 4 was filed 2026-08-07 covering transactions on 2026-08-05–08-07; no indication in the filing that it was late.

Context
The derivative entry is a granted award with a monthly vesting schedule (not an immediate exercise or sale). The open-market purchase represents a direct purchase by the CFO and increased his stake by 27,777 shares. These filings are factual disclosures required under Section 16; they do not explain the insider’s motives.